Our clinical trials Clinical trials Dose-Escalation and Expansion Study of BGB-16673 (B-Cell Malignancies - RECRUITMENT: OPEN) Project Title A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of BGB-16673 in Patients with B-Cell Malignancies Official Title A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies Project Summary Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts). Blood Disorders Marginal Zone Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Chronic Lymphocytic Leukaemia Small Lymphocytic Leukaemia Waldenstrom's Macroglobulinemia Patient Recruitment Details Patient recruitment status: Open Number of Patients (Globally) Undetermined.